When we looked at the LP genes, we discovered that antineovascularization agents, BCAAs, and enzyme inhibitors were the most promising agents for the early stages, whereas EGFR inhibitors, such as erlotinib, were only effective in the late stages and geldanamycin and staurosporine were potentially effective for US of PBC. Here, EGFR is linked to primary biliary cholangitis.